Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0165-1562
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
NNC0165-1562 is a peptide analog of Peptide YY (PYY) developed by Novo Nordisk for the treatment of overweight and obesity. It acts as an agonist at neuropeptide Y receptors, specifically targeting the PYY/Y2R signaling pathway to reduce appetite and promote weight loss. The drug is administered subcutaneously and represents a novel mechanism among anti-obesity agents. As of now, it has completed Phase 1 clinical trials in overweight or obese individuals[1][3][4][6].
- Other names
- NNC0165-1562NNC-0165-1562NNC 0165-1562
02
Targets
NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on NNC0165-1562.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0165-1562.